Gencurix
젠큐릭스 · 229000
Health Care Pharmaceuticals · KOSDAQ
Market cap US$45.5M (₩62.8B)
Overview
Gencurix develops blood-based cancer diagnostic tests, products that detect cancer-related genetic changes from a small blood sample rather than a tissue biopsy, a technique known as liquid biopsy.
Its tests are used by hospitals and clinicians to guide treatment decisions for confirmed cancer patients, with a focus on breast and lung cancer, and it is also developing early-detection tests for liver and colorectal cancer. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's product portfolio centres on its GenesWell and Droplex test lines, several of which have received regulatory approval and national health-insurance coverage in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$1.9M
- FY2024US$3.7M
- FY2025US$5.5M
Operating profit
- FY2023−US$8.1M
- FY2024−US$6.2M
- FY2025−US$4.8M
Net income
- FY2023−US$14.6M
- FY2024−US$3M
- FY2025−US$5.4M
Key ratios (FY2025)
Why it matters
Its breast-cancer prognostic test, GenesWell BCT, was designated an innovative medical technology by Korea's National Evidence-based Healthcare Collaborating Agency (NECA).
Price charts coming soon
Interactive price history isn't here yet. Would you use it?